Teladoc Health, Inc. (NYSE:TDOC) Stock Has Consensus Target Price of $7.54 According to Brokerages

Teladoc Health, Inc. (NYSE:TDOC) has been assigned a consensus rating of “Hold” from the sixteen ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $7.54.

TDOC has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Teladoc Health in a report on Wednesday, August 19th. Citigroup decreased their price target on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a report on Monday, August 3rd. Bank of America boosted their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Finally, Canaccord Genuity Group lowered their price objective on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, July 30th.

Teladoc Health Price Performance

TDOC opened at $6.20 on Wednesday. Teladoc Health has a 12 month low of $4.40 and a 12 month high of $9.89. The business has a 50-day moving average of $6.18 and a two-hundred day moving average of $6.89. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -6.26 and a beta of 2.14.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.04. The business had revenue of $606.93 million for the quarter, compared to analyst estimates of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The company’s revenue was down 4.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.19) EPS. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Equities research analysts anticipate that Teladoc Health will post -0.92 earnings per share for the current year.

Insider Buying and Selling at Teladoc Health

In related news, CEO Charles III sold 17,805 shares of Teladoc Health stock in a transaction on Friday, September 11th. The stock was sold at an average price of $6.10, for a total value of $108,610.50. Following the transaction, the chief executive officer owned 465,535 shares in the company, valued at approximately $2,839,763.50. This trade represents a 3.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Teladoc Health

Institutional investors have recently added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. grew its stake in Teladoc Health by 9.5% during the third quarter. Robeco Institutional Asset Management B.V. now owns 29,722 shares of the health services provider’s stock worth $172,000 after buying an additional 2,578 shares during the period. Counterpoint Mutual Funds LLC increased its position in shares of Teladoc Health by 1,017.4% in the third quarter. Counterpoint Mutual Funds LLC now owns 1,650,165 shares of the health services provider’s stock worth $9,571,000 after acquiring an additional 1,502,488 shares in the last quarter. Vontobel Holding Ltd. raised its stake in shares of Teladoc Health by 98.4% in the 3rd quarter. Vontobel Holding Ltd. now owns 93,210 shares of the health services provider’s stock valued at $541,000 after acquiring an additional 46,227 shares during the period. ABS Direct Equity Fund LLC purchased a new position in shares of Teladoc Health in the 2nd quarter valued at $1,513,000. Finally, WINTON GROUP Ltd raised its stake in shares of Teladoc Health by 402.4% in the 2nd quarter. WINTON GROUP Ltd now owns 227,100 shares of the health services provider’s stock valued at $1,926,000 after acquiring an additional 181,900 shares during the period. Hedge funds and other institutional investors own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc (NYSE: TDOC) provides virtual healthcare services and technology that connect patients with physicians, therapists and other healthcare professionals. Its platform supports general medical care, specialist consultations, mental health services, chronic condition management and related healthcare programs through digital and remote-care channels.

The company’s offerings include Teladoc’s telehealth services, BetterHelp’s online counseling and therapy platform, and chronic care solutions developed through Livongo, which Teladoc acquired in 2020.